Home > Insider Trading > Filing (0001735276-24-000110)

Filing Details

Accession Number:: 0001735276-24-000110
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-12-13 16:13:29
Reporting Period:: 2024-12-12

Accepted Time:: 2024-12-13 16:13:29
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1178670	Alnylam Pharmaceuticals Inc.	ALNY	Pharmaceutical Preparations (2834)	770602661

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1829252	Pushkal Garg	675 West Kendall Street Henri A. Termeer Square Cambridge MA 02142	Cmo & Evp Dev & Med Affairs	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2024-12-12	121	$247.48	17,336	No	4	S	Direct
Common Stock	Disposition	2024-12-12	186	$248.99	17,150	No	4	S	Direct
Common Stock	Disposition	2024-12-12	426	$250.08	16,724	No	4	S	Direct
Common Stock	Disposition	2024-12-12	778	$251.68	15,946	No	4	S	Direct
Common Stock	Disposition	2024-12-12	100	$252.94	15,846	No	4	S	Direct
Common Stock	Disposition	2024-12-12	140	$254.37	15,706	No	4	S	Direct
Common Stock	Disposition	2024-12-12	1	$255.80	15,705	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	431	Indirect	by Managed Account
Common Stock	250	Indirect	by Trust

Footnotes

This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 11, 2024.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $248.69 to $249.52. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $249.71 to $250.42. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $251.23 to $252.22. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $254.35 to $255.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
Represents shares held in trust, of which the Reporting Persons spouse is co-trustee. The Reporting Person disclaims beneficial ownership of these shares, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.